General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine
(2000; 80 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentAcknowledgements
Afficher le documentForeword
Ouvrir ce répertoire et afficher son contenuIntroduction
Ouvrir ce répertoire et afficher son contenu1. Methodologies for Research and Evaluation of Herbal Medicines
Ouvrir ce répertoire et afficher son contenu2. Methodologies for Research and Evaluation of Traditional Procedure-Based Therapies
Ouvrir ce répertoire et afficher son contenu3. Clinical Research
Ouvrir ce répertoire et afficher son contenu4. Other Issues and Considerations
Afficher le documentReferences
Ouvrir ce répertoire et afficher son contenuAnnexes
Fermer ce répertoireAnnex I. Guidelines for the Assessment of Herbal Medicinesa
Afficher le documentIntroduction
Afficher le documentAssessment of Quality
Afficher le documentAssessment of Safety
Afficher le documentAssessment of Efficacy
Afficher le documentIntended Use
Afficher le documentUtilization of these Guidelines
Ouvrir ce répertoire et afficher son contenuAnnex II. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicinesa
Ouvrir ce répertoire et afficher son contenuAnnex III. Report of a WHO Consultation on Traditional Medicine and AIDS: Clinical Evaluation of Traditional Medicines and Natural Productsa
Ouvrir ce répertoire et afficher son contenuAnnex IV. Definition of Levels of Evidence and Grading of Recommendationa
Ouvrir ce répertoire et afficher son contenuAnnex V. Guidelines for Levels and Kinds of Evidence to Support Claims for Therapeutic Goodsa
Ouvrir ce répertoire et afficher son contenuAnnex VI. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Productsa
Ouvrir ce répertoire et afficher son contenuAnnex VII. Guidance for Industry: Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplementsa
Ouvrir ce répertoire et afficher son contenuAnnex VIII. Guideline for Good Clinical Practicea
Ouvrir ce répertoire et afficher son contenuAnnex IX. WHO QOL (Quality of Life) User Manual: Facet Definitions and Response Scalesa
Afficher le documentAnnex X. Participants in the WHO Consultation on Methodologies for Research and Evaluation of Traditional Medicine
 

Intended Use

Product information for the consumer

Product labels and package inserts should be understandable to the consumer or patient. The package information should include all necessary information on the proper use of the product.

The following elements of information will usually suffice:

• name of the product
• quantitative list of active ingredient(s)
• dosage form
• indications

• dosage (if appropriate, specified for children and the elderly)
• mode of administration
• duration of use
• major adverse effects, if any
• overdosage information
• contraindications, warnings, precautions and major drug interactions
• use during pregnancy and lactation

• expiry date
• lot number
• holder of the marketing authorization.

Identification of the active ingredient(s) by the Latin botanical name, in addition to the common name in the language of preference of the national regulatory authority, is recommended.

Sometimes not all information that is ideally required may be available, so drug regulatory authorities should determine their minimal requirements.

Promotion

Advertisements and other promotional material directed to health personnel and the general public should be fully consistent with the approved package information.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013